scholarly journals Prevalence of Spirometra mansoni in dogs, cats, and frogs and its medical relevance in Guangzhou, China

2016 ◽  
Vol 53 ◽  
pp. 41-45 ◽  
Author(s):  
Qing Hong ◽  
Jieping Feng ◽  
Haijuan Liu ◽  
Xiaomin Li ◽  
Lirong Gong ◽  
...  
Parasite ◽  
2015 ◽  
Vol 22 ◽  
pp. 21 ◽  
Author(s):  
Arnaud Cannet ◽  
Mohammad Akhoundi ◽  
Jean-Michel Berenger ◽  
Gregory Michel ◽  
Pierre Marty ◽  
...  

Parasitology ◽  
1994 ◽  
Vol 109 (5) ◽  
pp. 611-621 ◽  
Author(s):  
Y. Kong ◽  
Y.-B. Chung ◽  
S.-Y. Cho ◽  
S.-Y. Kang

When immunoglobulin G (IgG) was incubated with Spirometra mansoni plerocercoid (sparganum), it was cleaved into Fab and Fc fragments. Fab/c fragments were also hydrolysed. The digestion was accelerated by dithiothreitol (DTT), indicating that cleavage of IgG heavy chain was due to a cysteine protease secreted into the medium. The responsible enzyme, of Mr 27 (± 0·8) kDa, was purified by a series of thiopropyl affinity, Sephacryl S-300 HR and DEAE-anion exchange chromatographies, either from worm extracts or from excretory–secretory products (ESP). The purified, thiol-dependent protease showed an optimal activity at pH 5·7 with 0·1 M sodium acetate but was active over the pH range 4·5–8·0. Its activity was inhibited completely by 10−5 M L-trans-epoxysuccinylleucylamido(4-guanidino) butane (E-64) and 1 mM iodoacetamide (IAA), but by only 53% using the specific cathepsin L inhibitor, Z-Phe-Phe-CHN2 (5 × 10−5 M). Partial NH2-terminal amino acid sequence was Leu-Pro-Asp-Ser-Val-Asn-Trp-Arg-Glu-Gly-Ala-Val-Thr-Ala-Val which showed 80% homology to human cathepsin S. Immunoblot analysis showed that sera from infected patients exhibited IgE antibody reaction. It is proposed that cleavage of immunoglobulin by an excreted–secreted, cathepsin S-like, allergenic protease is a mechanism of immune evasion used by the sparganum.


2019 ◽  
Vol 25 (4) ◽  
pp. 712-715
Author(s):  
Jun Zuo ◽  
Hai Gang Feng ◽  
Sha Sha Xie ◽  
Jun Tao Yang
Keyword(s):  

1993 ◽  
Vol 39 (7) ◽  
pp. 1525-1529 ◽  
Author(s):  
H A Fritsche ◽  
R J Babaian

Abstract We have assessed the feasibility of using fixed-limit criteria based on medical relevance and biological variation for evaluating the analytical performance of the prostate-specific antigen (PSA) test. The estimated within-subject variation of serum PSA is on the order of 10-20% at clinical decision points. The calculated performance goals of 5-10% CV are attainable with current immunoassay technology and agree with precision goals based on clinical experience and the current clinical use of the test. However, new clinical applications of PSA may require a degree of analytical performance that current methods may not be able to provide. The PSA model demonstrates the need for biologically based fixed-limit criteria for all tumor-marker tests.


Sign in / Sign up

Export Citation Format

Share Document